Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma

Angela Alama, Franco Merlo, Silvana Chiara, Maria Pia Muttini, Tiziana Guido, Guido Nicolò, Pier Franco Conte, Nicola Ragni

Research output: Contribution to journalArticlepeer-review

Abstract

The relationship between tumour proliferative activity, evaluated by thymidine labelling index (TLI), clinicopathological variables and clinical outcome, was analysed in a series of 64 chemotherapy-resistant, ovarian cancer patients. The median TLI of 4.6% (range 0.01-45.7) was used as the cut-off to discriminate rapidly from slowly proliferating tumours. Univariate analyses showed a significant advantage in survival for patients with TLI ≤ 4.6 (P = 0.0004), ECOG performance status ≤ 1 (P = 0.0001) and residual disease after primary surgery ≤ 2 cm (P = 0.019). Multivariate analysis demonstrated that performance status was the only independent prognostic variable, although TLI was the last covariate removed from the Cox's regression model.

Original languageEnglish
Pages (from-to)1079-1080
Number of pages2
JournalEuropean Journal of Cancer
Volume28
Issue number6-7
DOIs
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma'. Together they form a unique fingerprint.

Cite this